California court orders drug company executive to testify on AZT patent
April 07 2005 12:00 AM ET
GlaxoSmithKline CEO Jean-Pierre Garnier has been ordered by a U.S. district court magistrate judge in California to answer questions in a lawsuit brought against the company over its patent on the HIV antiretroviral drug Retrovir (AZT), AFX News reports. The lawsuit, filed by Los Angeles-based AIDS Healthcare Foundation, seeks to block the company's patent, claiming that the drug was developed by the National Institutes of Health with federal money in 1964 as a cancer drug. Under U.S. law, drugs developed with federal money must be sold at a reasonable price, which can be set by the courts. The lawsuit claims that because AZT was developed with NIH funds, the medication--and combination pills Combivir and Trizivir, which include AZT--should be sold at far cheaper rates. Garnier answered questions in a deposition in January, but AHF attorneys pressed for more questioning.
- Op-ed: 'Religious Discrimination' Laws Have Nothing to Do With Religion
- Indiana Newspaper Sends Big Message
- These Indiana Businesses Haven't Weighed in on Discrimination
- Subaru Comes Out Against Indiana's 'License to Discriminate'
- Gov. Mike Pence: 'This Is a Perception Problem'
- 12 Celebrities Who Said the “F” Word